End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.9 PLN | -2.45% |
|
-7.01% | +10.56% |
05-15 | Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02-14 | Biogened S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 20.39 | 17.19 | 20.88 | 21.12 | 31.2 | 44.21 |
Enterprise Value (EV) 1 | 41.81 | 38.06 | 35.42 | 34.86 | 50.72 | 59.16 |
P/E ratio | 17.9 x | 13.5 x | 16.8 x | 10.8 x | 9.23 x | 8.67 x |
Yield | - | - | 2.35% | - | 3.15% | 2.78% |
Capitalization / Revenue | 0.51 x | 0.37 x | 0.43 x | 0.32 x | 0.39 x | 0.46 x |
EV / Revenue | 1.04 x | 0.82 x | 0.73 x | 0.53 x | 0.64 x | 0.62 x |
EV / EBITDA | 5.83 x | 5.01 x | 5.24 x | 4.72 x | 4.5 x | 5.06 x |
EV / FCF | -54.4 x | 214 x | 2.38 x | 4.46 x | -16.6 x | 9.22 x |
FCF Yield | -1.84% | 0.47% | 41.9% | 22.4% | -6.04% | 10.8% |
Price to Book | 0.39 x | 0.32 x | 0.38 x | 0.71 x | 0.96 x | 1.2 x |
Nbr of stocks (in thousands) | 2,456 | 2,456 | 2,456 | 2,456 | 2,456 | 2,456 |
Reference price 2 | 8.300 | 7.000 | 8.500 | 8.600 | 12.70 | 18.00 |
Announcement Date | 14/05/19 | 14/05/20 | 13/05/21 | 30/05/22 | 30/05/23 | 29/05/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 40.24 | 46.63 | 48.33 | 65.32 | 79.62 | 95.56 |
EBITDA 1 | 7.171 | 7.604 | 6.761 | 7.388 | 11.28 | 11.69 |
EBIT 1 | 3.393 | 3.348 | 2.359 | 4.589 | 8.376 | 8.164 |
Operating Margin | 8.43% | 7.18% | 4.88% | 7.03% | 10.52% | 8.54% |
Earnings before Tax (EBT) 1 | 1.986 | 1.927 | 2.176 | 4.329 | 6.39 | 6.889 |
Net income 1 | 1.137 | 1.272 | 1.242 | 1.961 | 3.381 | 5.097 |
Net margin | 2.83% | 2.73% | 2.57% | 3% | 4.25% | 5.33% |
EPS 2 | 0.4629 | 0.5177 | 0.5054 | 0.7982 | 1.377 | 2.075 |
Free Cash Flow 1 | -0.7691 | 0.1781 | 14.86 | 7.82 | -3.065 | 6.417 |
FCF margin | -1.91% | 0.38% | 30.74% | 11.97% | -3.85% | 6.72% |
FCF Conversion (EBITDA) | - | 2.34% | 219.74% | 105.84% | - | 54.92% |
FCF Conversion (Net income) | - | 14.01% | 1,196.6% | 398.84% | - | 125.91% |
Dividend per Share | - | - | 0.2000 | - | 0.4000 | 0.5000 |
Announcement Date | 14/05/19 | 14/05/20 | 13/05/21 | 30/05/22 | 30/05/23 | 29/05/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 21.4 | 20.9 | 14.5 | 13.7 | 19.5 | 14.9 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 2.987 x | 2.744 x | 2.151 x | 1.859 x | 1.73 x | 1.279 x |
Free Cash Flow 1 | -0.77 | 0.18 | 14.9 | 7.82 | -3.06 | 6.42 |
ROE (net income / shareholders' equity) | 2.18% | 2.38% | 2.28% | 4.63% | 10.8% | 14.7% |
ROA (Net income/ Total Assets) | 2.62% | 2.5% | 1.75% | 3.97% | 7.91% | 6.81% |
Assets 1 | 43.41 | 50.83 | 70.77 | 49.36 | 42.73 | 74.82 |
Book Value Per Share 2 | 21.50 | 22.00 | 22.30 | 12.20 | 13.30 | 14.90 |
Cash Flow per Share 2 | 0.4300 | 0.4900 | 1.040 | 2.020 | 1.410 | 3.060 |
Capex 1 | 4.47 | 3.67 | 1.83 | 1.57 | 9.36 | 7.15 |
Capex / Sales | 11.1% | 7.87% | 3.79% | 2.4% | 11.76% | 7.49% |
Announcement Date | 14/05/19 | 14/05/20 | 13/05/21 | 30/05/22 | 30/05/23 | 29/05/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+10.56% | 12.44M | |
+26.58% | 45.33B | |
+38.49% | 25.36B | |
+27.90% | 16.7B | |
+20.89% | 14.59B | |
+72.03% | 14.26B | |
-0.05% | 6.79B | |
-10.35% | 6.67B | |
+13.07% | 5.62B | |
-8.87% | 5.73B |
- Stock Market
- Equities
- BGD Stock
- Financials Biogened S.A.